{"ticker": {"uuid": "31f31298-a544-49e1-8ab7-d3caae9549ed", "symbol": "TAK", "name": "Takeda Pharmaceutical Co Ltd ADR", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30", "summary": "Takeda Pharmaceutical announced it will host an earnings call on July 30, 2026, to present its first-quarter results for fiscal year 2026. Key participants will include President and CEO Julie Kim, CFO Milano Furuta, and President of R&D Andy Plump. The event will be held on Zoom", "url": "https://www.marketscreener.com/news/takeda-pharmaceutical-to-hold-earnings-call-for-fiscal-year-2026-1st-quarter-on-july-30-ce7f5ed2dc8cf627", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T23:41:02", "published_display": "15 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) 44th Annual J.P. Morgan Healthcare Conference summary", "summary": "Takeda Pharmaceutical Company presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic transformation towards an innovation-driven pharmaceutical business with a focus on gastroenterology, neuroscience, and oncology. The company highlighted eight la", "url": "https://quartr.com/events/takeda-pharmaceutical-company-4502-44th-annual-j-p-morgan-healthcare-conference_3sW6P27d", "source_name": "Quartr", "published_at": "2026-07-14T22:13:20", "published_display": "14 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda to Invest $30 Million in Indonesia's Plasma Medicine Industry", "summary": "Japanese biopharmaceutical company Takeda plans to invest $30 million in the initial phase of developing Indonesia's plasma-derived medicines ecosystem. This investment, spread over two years, aims to establish a nationwide plasma collection network and will support technology tr", "url": "https://jakartaglobe.id/business/takeda-to-invest-30-million-in-indonesias-plasma-medicine-industry", "source_name": "Jakarta Globe", "published_at": "2026-07-14T10:50:21", "published_display": "14 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com", "summary": "This article briefly reports on a Form 144 filing by Takeda Pharmaceutical Company Limited for July 13th. The filing indicates insider intent to sell restricted stock. This is a standard regulatory disclosure within financial markets.", "url": "https://ng.investing.com/news/stock-market-news/form-144-takeda-pharmaceutical-company-limited-for-13-july-93CH-2596371", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:44:25", "published_display": "13 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to resell 51,579 ADSs under Rule 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOVWZpZU1KX1VkVHB6RlNFZ3kySFBqbDdaRWs4SjBVUWZCdHZ5UmIySzk2Vm5mSGJydmNRQUF2bFA1Qy1JTVZXblF1Y3JVcFR6alZlMGtjRmQxVnZfYlFWeDY3TXI2WXRPd083LVRhY2RDcHRXN3lrcmxPdC1Qakx6dndzdFJFMk42QXZhYk9INkJ1d2lzYUcxdndWRlFZLTMtNGs1U1Q2SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:33:10+00:00", "published_display": "13 Jul 2026 10:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) affiliate plans Rule 144 sale of 27,197 ADSs", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSkpxQ0o0ckljWHNsUEdOU3JjaVMxbG55U1RCakpMMlF4dHAxR0h4OHRLMUtTdkJLcEhIckwydU4tQnc2QnVXeDBYTG5KWE1sRTY4UUNWT3h1Ny03bWJrNEJBakhEcVVoLURoYXlhUHo1djc5LWU5dnVzVi1SZExaTGVnRmZDTXhET0dsYXplczl1emZBV29PT0NQODBrSUNOXzlNenVyaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) insider plans sale of 19,754 ADSs from vested RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPbmpNSGtyY2xvQmZMSmx5SFRUMm55T2JFdTF2bDI5XzU2dE54VUtVenhqczIwQlZhZGpCOHpiTGhMNEhBNk4wbmZaZ2hGek5KR0JWRzZmZnp0SzJDZVlvSzhMcHNUX09rVjBJQ0swQkgwazVVcnRHLWZhMXp1M1hWZmtZdkNHeERSMFhReEp2R192SnZoS25tOGZPYzkwN2VWQ1JsbVpqYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOX3JTdnE5MzViV1h6R2RadjF5dlB3cFk1OHlpekNnYURMdzM2RWh4cWxWRDl3NFR5akFmcG1WRHBzMzN0MWlhN0dfYnFIcXlJNGNBQWVGZFVBREpMS05BM2psMmJMR2Rnel9kTC0zV2ltS0RqV0Jka28tY0NCc0VPckF2akIwR19uOVRLS3Zja3BKMVpBZmx1dDBkSFpuVXVydks4RzFQOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) holder to sell 33,454 ADSs valued at about $560K", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQNUwwYno4eDgtRjVwVzFSSEQwWHpuSkdyekhaREFob3M0R3JkRUUya2RHTkpMSW5QMVYxSnFOOXdyVUQtVFZxREN2VExlUDZGQUZiejF0bHZiM3dNYlJnWnVwVkp1R016U3NHRVpBcTFGRmQ2RjkwbGt6NnhFLVk1RkhVbVpsVEhQRFc5aFdyTlg4QmQ5QVpNa2JEVGUya0Jad0RWcXVITQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:57+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder plans sale of 15,188 ADSs under Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWWsyOXNYZzNDbGlYZ1BNNWlYM0psczlod1VXWkgtT1U1MEl4ZlI1UWFHNjltVkdGOWplMFR0WHZSN2IwTmtNR3QtaDFCQTVueUZFNzh2aVBWeVNyTHgzQy1ieUVDYTFjajI2ay1mWEE2QThnTWFRRUxLUUVCXzdKTGt1aXlORlA2anZWWTJ4XzFZMWd0WHBNeU41VEJyc3Flb2pxcElySQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (NYSE: TAK) files Form 144 for 50,582 ADSs from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPa2l5MDhGWXE4NmdvMy05bE9RRG9ZaWpySWlYUXIteEk2cFZuQ3pieUpBN00yUXRGSXRaTFd3NDRidWY3YzhhSTR2X0xhRW5HOVRfZEIyNVNkVlBCQTZzYnBJNUJ5X2x1LWNxMllpS05TZTNrdUJvbm1ucTFxcUp5U3dEMjVKU0tldXpORG80MXlYbGc1VzJ1b0xVT2ZHVHhvNHlEblZqZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) holder to sell 179,239 ADSs worth about $3.0M", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSWxTWlZmRFhBbmUyNy1XSmZnZ2hKbWppSWttMXllZ25wcHAxd0dmNE5EcGJGdmFmTVA3ZDRTZ3VyY0NQcGdWRGpyY1pCNE1rVkRqdEZ3bkNVQ2VlQTBraGl6WGlJcFQxZ3JfS0pWTlhZTFd4eHg2VEtqcU1qYjFPM04ySV83OE9EWkVpUUZrZTE5bzBEM0FaN1c2N0llcjJ6dTFDSUFkbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUkdMUUEwZ1daVjRQVk5BLWp5WnNHWlo4djBzSW9SWFNBN2VaSUlZWFRHRVdlS2x6LWgzb0kweFlXVWcyMjdpYS0wdmU0LTdqczdsOUhGT0owcHRzMEZ0RV8zR25zY0pnUXpZWTU1SlA2b1Rva0NHTU9QM0VSbDNqdHdhQ01nT2lQa3JVZkZzMy05RGxCckNkTE04czhOQ0xKczRGUDVybw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) plans 33,696 ADS NYSE sale after prior RSU sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQaU1USjlrNkVmSW5WVEM1RHVCZ2ZybFRVOTBSamNsV1BPZlZQUkhJbTB0UEtyckg1aUtIaHhjZjc1R2hhakQ3R1FnZFg0ZHhQTUU4dUhaSVQ0LWQ3dXpfbTJGWGZfWElDT3BtYl95YkI1b2J3Z3ZRM19GSWhNemVqYnFwMHpBbXdJZTc1T2dLWjM3bVhEck9SeWY4aXE2bFJKdU9KS01DRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:23+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSE", "summary": "Takeda Pharmaceutical Company Limited has filed a Form 144 notice to sell up to 7,889 American Depositary Shares (ADSs) on the NYSE through Interactive Brokers LLC, on or after July 13, 2026. The aggregate market value of these ADSs is indicated as $132,148.97. The filing also no", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-37c282f29f2d.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:11", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filing", "summary": "Takeda Pharmaceutical Company Limited filed a Form 144 SEC notice regarding the proposed sale of 190,406 American Depositary Shares (ADSs) on the NYSE. These ADSs were acquired through vested Restricted Stock Unit Awards as part of compensation on July 1, 2026. Interactive Broker", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-38c4d25bcb86.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:10", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850", "summary": "Takeda Pharmaceutical Company Limited has filed a Form 144 notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC. The aggregate market value of these shares is approximately $416,850 and the sale is expected to occur on or about ", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-7acd19367ec8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:10", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) Launches Plasma Ecosystem Initiative in Indonesia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMGk2ejgzTlRSUEgyY01Iam5Fa1MteVBuRnRBZk9nbHF4Z3ZWT2JBdktXM0k4am5UYnJuaDUzVEEtWDJ6TVpKOUJhelVtM3U3cXpTNTdLbGJhU19kSWVaLVZ2V1o5c0FzUVdLTGh6QjF6TGMyR2VfWGFLRE1GYjQzejM1c2EtdG5fUmFiZFYxaS1vYm1meEZtZXFRRjA4bVlUUVVoSTRDeGJuWmNhTV9uRUZMYkRkYmFUTlVNQ3dOTUY1NWhTd3hYYUZtU0Fad25PQUEta2ZZT1dMalRwbFJseF9yU3NqN3U0Q1E?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T09:03:23+00:00", "published_display": "13 Jul 2026 09:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda and Indonesia partner on plasma-derived therapies", "summary": "Takeda is collaborating with the Indonesian Government to establish a plasma ecosystem and improve access to plasma-derived medicinal products (PDMPs) in Indonesia. The company plans to invest up to $30 million to launch a national plasma donation pilot program, with initial dona", "url": "https://www.pharmaceutical-technology.com/news/takeda-indonesia-plasma-derived-therapies/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-13T09:45:08", "published_display": "13 Jul 2026 09:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, Takeda and Capricor on the verge of notching big drug approvals", "summary": "", "url": "https://finance.yahoo.com/m/84010ace-bef0-3bf0-b760-6f87a2290af8/moderna%2C-takeda-and-capricor.html", "source_name": "Pharma Voice", "published_at": "2026-07-13T08:20:00+00:00", "published_display": "13 Jul 2026 08:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/takeda-indonesian-government-launch-program-074538219.html", "source_name": "MT Newswires", "published_at": "2026-07-13T07:45:38+00:00", "published_display": "13 Jul 2026 07:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/takeda-indonesian-government-announce-landmark-230000564.html", "source_name": "Business Wire", "published_at": "2026-07-12T23:00:00+00:00", "published_display": "12 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indonesia backs Takeda plan for national plasma donation network and new jobs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcHpvRG1iVnQxMlp4R3RqYnJZWlN4a3lrT2lkbmtsZTkwel9faGxOYVlpMGZkdGlaSEFnN1NVdmNmX2s4UWE1T0hxVFdpdGxPQ2ZfVlN0Umx0RTM4YkRxRXotSDhfVVlQTUJCQWU3bXU2dno2OVNEWTA0WVA0a3NLOGktY3pKYVBPZGdXRFpaa1RDRjZsNFlNM3NibzVVOGJyTFZjcFVIY3hPMVRIQWphOVJ4anB1SzNYUkRiNWpzbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-12T23:00:00+00:00", "published_display": "12 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) TD Cowen 46th Annual Health Care Conference summary", "summary": "Takeda Pharmaceutical Company presented at the TD Cowen 46th Annual Health Care Conference, highlighting a strategic overview that included successful Phase III results for three new molecular entities (rusfertide, oveporexton, and zasocitinib) in 2025 and an upcoming CEO transit", "url": "https://quartr.com/events/takeda-pharmaceutical-company-4502-td-cowen-46th-annual-health-care-conference_3sW6PWd4", "source_name": "Quartr", "published_at": "2026-07-11T23:10:10", "published_display": "11 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Study Update Summary", "summary": "Takeda Pharmaceutical Company (4502) released a study update for Oveporexton, an oral orexin receptor 2 agonist, which showed significant and clinically meaningful improvements in treating narcolepsy type 1 (NT1) across multiple endpoints. Two global Phase III trials demonstrated", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-study-update_3sW6gnqy", "source_name": "Quartr", "published_at": "2026-07-11T10:39:43", "published_display": "11 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?", "summary": "Takeda Pharmaceutical (TSE:4502) has partnered with Insilico Medicine's Pharma.AI platform for drug discovery, leading to renewed investor interest. Despite an 8.5% year-to-date share price increase and a 26.82% one-year return, a recent 90-day decline of 6.94% prompts questions ", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-pharmaceutical-tse4502-taps-pharmaai-for-drug-discove/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:40:29", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) outlines board independence, ESG and shareholder engagement", "summary": "Takeda Pharmaceutical Company Limited has filed a detailed Corporate Governance Report, highlighting its compliance with Japan\u2019s Corporate Governance Code. The report emphasizes the company's commitment to board independence with a majority of independent external directors, robu", "url": "https://www.stocktitan.net/sec-filings/TAK/6-k-takeda-pharmaceutical-co-ltd-current-report-foreign-issuer-66709a178019.html", "source_name": "Stock Titan", "published_at": "2026-07-09T09:48:28", "published_display": "09 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Q4 2025 earnings summary", "summary": "Takeda Pharmaceutical Company announced its Q4 2025 earnings, reporting significant revenue and core operating profit growth, driven by strong performance in growth and launch products. The company also highlighted efficiency program successes, pipeline advancements, and an incre", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-q4-2025_3sW6gxaK", "source_name": "Quartr", "published_at": "2026-07-08T22:11:54", "published_display": "08 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Plan", "summary": "Takeda Pharmaceutical announced it has completed the issuance and disposal of shares as part of its incentive plan. The shares were allocated to a trust for the \"Board Benefit Trust (BBT)\" and \"Employee Stock Ownership Plan (ESOP)\" schemes. This move aims to enhance shareholder v", "url": "https://www.moomoo.com/news/post/72648686/takeda-pharmaceutical-completes-share-issuance-disposal-under-incentive-plan", "source_name": "Moomoo", "published_at": "2026-07-08T12:42:14", "published_display": "08 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Q1 2026 earnings summary", "summary": "Takeda Pharmaceutical Company's Q1 FY2025 revenue declined 8.4% year-over-year to JPY 1,106.7 billion due to Vyvanse's generic erosion and FX headwinds, but net profit rose 30.4% to JPY 124.2 billion. Growth and launch products, comprising 50% of revenue, grew 5% at CER, showing ", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-q1-2026_3sW6goVg", "source_name": "Quartr", "published_at": "2026-07-08T09:42:14", "published_display": "08 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) completes long-term incentive share issuance and treasury share disposal", "summary": "Takeda Pharmaceutical Company Limited announced the completion of its long-term incentive share issuance and treasury share disposal for employees outside Japan. The company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, totaling 85,229,400,450 yen. Thi", "url": "https://www.stocktitan.net/sec-filings/TAK/6-k-takeda-pharmaceutical-co-ltd-current-report-foreign-issuer-6287e1e9db04.html", "source_name": "Stock Titan", "published_at": "2026-07-08T09:40:50", "published_display": "08 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda\u2019s orexin program: The hits, the misses and the payoff", "summary": "Takeda is nearing the market with oveporexton (TAK-861), an OX2R agonist for narcolepsy type 1, after decades of research into orexin signaling's link to the disease. The company's success is attributed to its unwavering commitment, rapid adaptations to trial designs, and strong ", "url": "https://www.biocentury.com/article/659997/takeda-s-orexin-program-the-hits-the-misses-and-the-payoff", "source_name": "BioCentury", "published_at": "2026-07-08T00:13:00", "published_display": "08 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) director Bruce Broussard receives 3,800 ADS RSUs and 1,319 tax awards", "summary": "Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard received 3,800 American Depositary Shares (ADS) as restricted stock units (RSUs) and 1,319 Tax Obligation Award units. These equity-based awards, rather than open-market purchases, vest on June 1, 2029, and increase his d", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-89f6a95cdac9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:40:50", "published_display": "07 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 22,570 RSUs to chief HR executive", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNNk9FbDJxSUFVbl9ibmkzVDNMOXpsSEtNZmxqYlNRU0Z6aV9SeVJtZ1JzdnlRMFVBOTdmVE1CdVk5ZGI1UnVqV1NncTVLcVJKU25Fa25iY2JqWE1BU3NNbGdOaTY1UUdlSW9qZzAzcXRtOXhtMWhWN196MHcyMXg1TnNqc3dJd3RGYXlUOTZ0VXhPVGVNcDBVV3hvZzkxQXBXU21qbHFNYmdfMENXcHRXZFdDbWF6RXUzWW1sNFl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:06:58+00:00", "published_display": "06 Jul 2026 22:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 27,586 RSUs to strategy head Marcello Pignagnoli", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaVlEX19vX1lmWWxwNHEtdFpSU3pibkNxUDhMak1RcERpLUlBQTh1RzF4RWt1V0Yzam42SlVleGlvT2h2QWJqbWtKNV9TcG51UTNiV1N6SXdWaXRCRnlGaG1sN180WXp6NU0wX25ZUE5ibHdMOTBNcG9CTkJSNHZiS2dMTXRNTU1lWjAzcTRyRW8xRW5IbV9iTk15VkJUZTRGXzE2c0E3aXNyWFVLc09DMldzVUEwSVhVZ0RwWjhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:05:10+00:00", "published_display": "06 Jul 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) R&D head receives 125,390 RSUs, updates holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOLVBGOUhkelgxQjlOS0pIS2pJbHNMRWZkdi1KYkZRUWFiRGppdWVQWGhxeGJPdGFrYUxIb1g4ZkUyRDFPTTZmSlhsMXdrODRsYkpnT1dERHhLOFNtM29HenBqRDNOVk56UDBaaXZaeTl1c25fbFdNZVNLZ1BjYVpndTdUaXpoNlYxazFvYkdGMGtQR3hVVFUzT2lPYjYwclhUdDNtZ3ozc3hUbWRneUQ1MHp1X1k2dWphLXhRWjZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:01:36+00:00", "published_display": "06 Jul 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 49,558 ADS RSUs to IBU president Platford", "summary": "Takeda Pharmaceutical (NYSE: TAK) granted 49,558 American Depositary Shares (ADS) as Restricted Stock Units (RSUs) to Giles Richard Platford, President, IBU, as part of his compensation. These RSUs were awarded at no cash cost and will vest in three equal annual installments star", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-788156463a7c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director gets RSU grant and manages tax-related share disposition", "summary": "Takeda Pharmaceutical director Kimberly A. Reed reported new equity awards and tax-related share transactions. She received a grant of 3,800 Ordinary Shares as restricted stock units vesting on June 1, 2029, and 1,319 Tax Obligation Awards. Additionally, 1,152 Tax Obligation Awar", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b57beba8c391.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) executive granted 30,094 RSUs, lifting holdings to 87,674 ADS", "summary": "Takeda Pharmaceutical executive Shannon Elaine Mary received a grant of 30,094 Restricted Stock Units (RSUs), increasing her total holdings to 87,674 American Depositary Shares (ADS). These RSUs, which were awarded as part of compensation at a $0.00 stated price, will vest in thr", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-39c2d023174c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) chief communications officer receives 18,808 RSU share award", "summary": "Takeda Pharmaceutical's Chief Communications & Government Officer, Jennifer Marie Smoter, was granted an equity award of 18,808 American Depositary Shares in the form of restricted stock units (RSUs). These RSUs will vest in three equal annual installments starting on July 1, 202", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-bf62fcd1cda7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 37,616 ADS RSUs to tech chief Ricci", "summary": "Takeda Pharmaceutical (NYSE: TAK) has granted its Chief Data & Technology Officer, Gabriele Ricci, 37,616 American Depositary Shares (ADS) in the form of restricted stock units (RSUs). These RSUs were awarded at no cost and will vest in three equal annual installments beginning J", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b78bf3c22de2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) unit president gets RSU grant and tax awards", "summary": "Asuka Miyabashira, President of Takeda Pharmaceutical's Japan Pharma Business Unit, received a grant of 1,500 Ordinary Shares and several Tax Obligation Awards. This transaction increased her direct ownership to 4,500 shares. Additionally, 1,022 vested Tax Obligation Awards were ", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-413d92923acf.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director Paulus Stoffels receives share and tax-linked awards", "summary": "Takeda director Paulus Stoffels reported receiving equity compensation, including 3,800 Ordinary Shares and 1,307 Tax Obligation Awards. These awards are part of his director compensation, with the shares going into his direct holdings and the tax awards vesting as cash on June 1", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b610520200b2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:11:56", "published_display": "06 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Paulus Stoffels files initial Form 3 for Takeda (NYSE: TAK)", "summary": "Takeda director Paulus Stoffels has filed an initial Form 3 with the SEC, indicating his insider status as a director of the company. This filing is a baseline disclosure and reports no transactions or derivative positions in Takeda's securities. It serves to establish his benefi", "url": "https://www.stocktitan.net/sec-filings/TAK/form-3-takeda-pharmaceutical-co-ltd-initial-statement-of-beneficial-o-e98ee9e0a095.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:42:33", "published_display": "06 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 43,886 RSU-linked ADSs to oncology unit chief", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOFRKNlB2aGNkZk1HaktnU0t2cDA4RGNxTGVRUVppLTBsMkktaHd6U1lZelhkdWFTbF9KSzVMT0NUQ0FTOVFFNTUyaGNSaXZkaXVvVUJzSU9vejhQZFNXUEs5SlhVN0NrWFlscGZDZFZhVjA0eUxwTHlkS0phLXY5c3AzYmdINEJXdndwR1ZwMkpnMk5ZZmVfYXhyTkVEMlZsWDVkc29Dc25aMEdvZUI5WTl3WEZaQTNqVnJFSjRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) U.S. Business president awarded 50,156 RSUs in ADS grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQVzg3UVZUTEd5cDJPVHdManZiSUZCQzdjSFlpNldudnIzMG1PX0tLMTA1ek1nUkJCa0tiZWlxRGE4U1NPMXFaQ1BvaEdrMTNqRHNTbUVNd2NNdUtHVng4UmhpdVZMRDVEUktYSzRubWZYbUltYUN2dHlIS056cktNUFE5QVY3Z0VXeVlpMlMzeDZfVi02V3ZicnBpbGd1UE5FcjloYUNtanpBZkd0VWlIVS0xTGNZeVh0X2FfajJR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director awarded RSUs and settles tax obligation awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQejFvMUxrYXJTS285T2Z2ZVJSanVkT0dEX3BiV0c5dExLSk91aUlTSkt3MkJMbUhPUVQ0dDZOZUd3Nm5RZ3ZfU01CU0c5eEozS3NWWkVESS1JR2tXMjBXZzVNM05lb2xxQWctVWFKQ1hqOWpSQTJkdjYtT3EydGpPMlVaX1B6TXBVXzRzangyUEZoU0Vra29kZGhpenREUU8yOUNaaHZyVmhoY2x1TGdZeU9xd3cwUGw3a2ZEbmln?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 45,140 RSUs to Chief Transformation Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbk9jdTlYTWJLSmRBRkhUWFlOOWNtd2ljMXpyTlB3RnlhdDNWaGlXLTRxUWlwSGlTSVM1ckRMc09UTnZ2c0F6VHVqSEI3S0J4YkFHOTJZR0JFbmVmd1p4b2ppQ1BNWTFEYnZhYXRBLUI4YWV6WS00azF0UXZQWmZnT0hlemhpellTVm9Sai1FSWlSYUJwMV82QkhxOXdfTTFic3l5emI1TU41d0VmeG0xZUdsMkNQblFOX1BzQlh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director logs RSU awards and tax-related share disposition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNZDFmb3BzTDc3UHVzWnkybVFuWml2RlptLU4wUGNJRWx0RDMxNk1PV21fbXdMbEN3WjlhYjdJSGxKdDBBUmNrUVhZaDZNZUx6cm9jWnJJRFItOHVmcEo3Wnp1SEJXVU9MLUJwQ2dDbF9ZdS1MeWROYmdIR0RUaXgtdXRVR3c3Zmc0b1pnNWlDeG5nQTZoYUc5RzZGdURxNHRKN3FKSUwxenI5WWZ3dF8ySkZ4b09ybS1WeW96R1dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?", "summary": "Takeda Pharmaceutical's stock rose 5.3% following its collaboration with Insilico Medicine to use its Pharma.AI platform for drug discovery, a deal potentially worth up to US$600 million plus royalties. This partnership, alongside the new CEO Julie Kim, could significantly influe", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-pharmaceutical-tse4502-is-up-53-after-new-insilico-ai/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T03:40:22", "published_display": "06 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks", "summary": "This article lists various ETFs that include Takeda Pharmaceutical Co. Ltd. Sponsored ADR stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of Takeda stock, issuer, management style, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/LSE-0A87/etfs/", "source_name": "TradingView", "published_at": "2026-07-06T03:40:22", "published_display": "06 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine", "summary": "", "url": "https://finance.yahoo.com/technology/ai/articles/takeda-makes-fresh-ai-drug-173105795.html", "source_name": "Benzinga", "published_at": "2026-07-05T17:31:05+00:00", "published_display": "05 Jul 2026 17:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TSE:4502) Stock Still Looks Slightly Undervalued Overall", "summary": "Takeda Pharmaceutical (TSE:4502) stock has shown strong returns over the past five years but presents a nuanced valuation picture, screening as undervalued in 4 of 6 checks according to Simply Wall St's framework. The company's P/S ratio of 1.9x is slightly above the industry ave", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-tse4502-stock-still-looks-slightly-undervalued-overal/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-04T08:10:03", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOMnlTVE96dXFleVkwdWRIQlhkc1VHWWhjSG1qbmVhVVRjYm83NzBOaWczNHZJMm5fQjRoY21SRXc5V1BKalk1RHhocXZJU1BhdmhwVUUtVTUybDNUUFd5MzdjSjZIVVNwQ3hwQ3p5WGgyeGtBZ2Nad2laTXpVM3YxQ0s5bjhhemJlVUZwMFdZS25Sak52cTAzd0d2S1YwWjZBVVFHRw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda appoints Julie Kim CEO as 18-month transition ends", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTDFIVEpPX3pkdmUtZ2VidzZ6aFhQeVpEQlBQSHBDT1o0OGs2N0tEcU5tVkttT3NibU1qeXl4OXhoOW1US00zSHJhSGFsZVNKczd4R24yLUxlOGNkb2Z4YnFEVU9aTGUweGRpallGWGs2V1htOThUdHM5eWxjRk1wOExUbWZTSk5wdzlsMzZNdXo3bUYwaGJ4QVRRWmkwX1RzU1FlMVBmYXhPZ2J3anFtdGtCRGFjUWliVlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical: The Downside Was Forecastable (NYSE:TAK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOY3BEQzFhQ0I0dTNQTEFZVnRFXzdadzRDNlhRZ2h5cXNCNFVIbnRtVi1Ydnd4TmJHdHBOYmVTWjgwbkQtekZRRTRsRDFTVGJGR2tWbnhpdXRfanZQS0xhZGo4WmRja3l6cG0wN1B5Z3F5ZUR4YzJNYllONmE4bXBsV3hiUjJsRVpJaHc3OEU3cTFQVDlkWTJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQRkFWZ3o4c21ET2tVMzVGNDFhVS1OZnhIZU5uOEh5akxTT2JuV0ZvaEtLRl9DNHZBS1VwOVZWNlBnZEdYOVYta0ZnbmNmaUhoVDFURjJqT1QyZnBPWjJzenlmUnc5dGhyeW5NUWN0V1JyTE12WEtaVEluUm8wQ1FwLUdXZVFfU1JFTEhha0lmcXcxaF9hd19jcTZmSzY3N1F5cWlPal9jbGNIajNhbFQ4?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNckpfeDdTSDBxVTFueWdHZHRya2tPcDVKdWxJR005c0Q1MjdNRXE0cG1OalM2LW1yMUxuekZXOHhlRFcydVlibUgwVnNSRkdQd2lRTUhhR0ItVk5ub2loSGFzanNwX1BLLXlpZklYc3RXTWJodDdWNU0wLTd3dXBPOXBCV3VhdGZSb2FzTzk2SmNLTkRfcFJOV3E2YnJwOEFzdjRMQkNROHlxOGwxRVRR?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPV2EwUkxKSVZNaEJLQ0o0NHFHdFZmQ29LTmt1NklBdnVFTHVueHZRTWRTSktZSk1BM1l6LS1sa1RTTXNnOEYtSUcyZ2JBU1V5a0pjRkRiOF9iN1hWNjRqOFpPalRTN0cydVNfbVM1NnB3MERnYmJWOFFKcmM4eE9aMzBabV9mTGgtUUN0dHpTWXM?oc=5", "source_name": "Market source", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30", "summary": "Takeda Pharmaceutical announced it will host an earnings call on July 30, 2026, to present its first-quarter results for fiscal year 2026. Key participants will include President and CEO Julie Kim, CFO Milano Furuta, and President of R&D Andy Plump. The event will be held on Zoom", "url": "https://www.marketscreener.com/news/takeda-pharmaceutical-to-hold-earnings-call-for-fiscal-year-2026-1st-quarter-on-july-30-ce7f5ed2dc8cf627", "source_name": "www.marketscreener.com", "published_at": "2026-07-15T23:41:02", "published_display": "15 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) 44th Annual J.P. Morgan Healthcare Conference summary", "summary": "Takeda Pharmaceutical Company presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic transformation towards an innovation-driven pharmaceutical business with a focus on gastroenterology, neuroscience, and oncology. The company highlighted eight la", "url": "https://quartr.com/events/takeda-pharmaceutical-company-4502-44th-annual-j-p-morgan-healthcare-conference_3sW6P27d", "source_name": "Quartr", "published_at": "2026-07-14T22:13:20", "published_display": "14 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda to Invest $30 Million in Indonesia's Plasma Medicine Industry", "summary": "Japanese biopharmaceutical company Takeda plans to invest $30 million in the initial phase of developing Indonesia's plasma-derived medicines ecosystem. This investment, spread over two years, aims to establish a nationwide plasma collection network and will support technology tr", "url": "https://jakartaglobe.id/business/takeda-to-invest-30-million-in-indonesias-plasma-medicine-industry", "source_name": "Jakarta Globe", "published_at": "2026-07-14T10:50:21", "published_display": "14 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com", "summary": "This article briefly reports on a Form 144 filing by Takeda Pharmaceutical Company Limited for July 13th. The filing indicates insider intent to sell restricted stock. This is a standard regulatory disclosure within financial markets.", "url": "https://ng.investing.com/news/stock-market-news/form-144-takeda-pharmaceutical-company-limited-for-13-july-93CH-2596371", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T23:44:25", "published_display": "13 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to resell 51,579 ADSs under Rule 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOVWZpZU1KX1VkVHB6RlNFZ3kySFBqbDdaRWs4SjBVUWZCdHZ5UmIySzk2Vm5mSGJydmNRQUF2bFA1Qy1JTVZXblF1Y3JVcFR6alZlMGtjRmQxVnZfYlFWeDY3TXI2WXRPd083LVRhY2RDcHRXN3lrcmxPdC1Qakx6dndzdFJFMk42QXZhYk9INkJ1d2lzYUcxdndWRlFZLTMtNGs1U1Q2SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:33:10+00:00", "published_display": "13 Jul 2026 10:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) affiliate plans Rule 144 sale of 27,197 ADSs", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSkpxQ0o0ckljWHNsUEdOU3JjaVMxbG55U1RCakpMMlF4dHAxR0h4OHRLMUtTdkJLcEhIckwydU4tQnc2QnVXeDBYTG5KWE1sRTY4UUNWT3h1Ny03bWJrNEJBakhEcVVoLURoYXlhUHo1djc5LWU5dnVzVi1SZExaTGVnRmZDTXhET0dsYXplczl1emZBV29PT0NQODBrSUNOXzlNenVyaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) insider plans sale of 19,754 ADSs from vested RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPbmpNSGtyY2xvQmZMSmx5SFRUMm55T2JFdTF2bDI5XzU2dE54VUtVenhqczIwQlZhZGpCOHpiTGhMNEhBNk4wbmZaZ2hGek5KR0JWRzZmZnp0SzJDZVlvSzhMcHNUX09rVjBJQ0swQkgwazVVcnRHLWZhMXp1M1hWZmtZdkNHeERSMFhReEp2R192SnZoS25tOGZPYzkwN2VWQ1JsbVpqYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOX3JTdnE5MzViV1h6R2RadjF5dlB3cFk1OHlpekNnYURMdzM2RWh4cWxWRDl3NFR5akFmcG1WRHBzMzN0MWlhN0dfYnFIcXlJNGNBQWVGZFVBREpMS05BM2psMmJMR2Rnel9kTC0zV2ltS0RqV0Jka28tY0NCc0VPckF2akIwR19uOVRLS3Zja3BKMVpBZmx1dDBkSFpuVXVydks4RzFQOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:58+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) holder to sell 33,454 ADSs valued at about $560K", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQNUwwYno4eDgtRjVwVzFSSEQwWHpuSkdyekhaREFob3M0R3JkRUUya2RHTkpMSW5QMVYxSnFOOXdyVUQtVFZxREN2VExlUDZGQUZiejF0bHZiM3dNYlJnWnVwVkp1R016U3NHRVpBcTFGRmQ2RjkwbGt6NnhFLVk1RkhVbVpsVEhQRFc5aFdyTlg4QmQ5QVpNa2JEVGUya0Jad0RWcXVITQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:32:57+00:00", "published_display": "13 Jul 2026 10:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder plans sale of 15,188 ADSs under Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWWsyOXNYZzNDbGlYZ1BNNWlYM0psczlod1VXWkgtT1U1MEl4ZlI1UWFHNjltVkdGOWplMFR0WHZSN2IwTmtNR3QtaDFCQTVueUZFNzh2aVBWeVNyTHgzQy1ieUVDYTFjajI2ay1mWEE2QThnTWFRRUxLUUVCXzdKTGt1aXlORlA2anZWWTJ4XzFZMWd0WHBNeU41VEJyc3Flb2pxcElySQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (NYSE: TAK) files Form 144 for 50,582 ADSs from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPa2l5MDhGWXE4NmdvMy05bE9RRG9ZaWpySWlYUXIteEk2cFZuQ3pieUpBN00yUXRGSXRaTFd3NDRidWY3YzhhSTR2X0xhRW5HOVRfZEIyNVNkVlBCQTZzYnBJNUJ5X2x1LWNxMllpS05TZTNrdUJvbm1ucTFxcUp5U3dEMjVKU0tldXpORG80MXlYbGc1VzJ1b0xVT2ZHVHhvNHlEblZqZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) holder to sell 179,239 ADSs worth about $3.0M", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNSWxTWlZmRFhBbmUyNy1XSmZnZ2hKbWppSWttMXllZ25wcHAxd0dmNE5EcGJGdmFmTVA3ZDRTZ3VyY0NQcGdWRGpyY1pCNE1rVkRqdEZ3bkNVQ2VlQTBraGl6WGlJcFQxZ3JfS0pWTlhZTFd4eHg2VEtqcU1qYjFPM04ySV83OE9EWkVpUUZrZTE5bzBEM0FaN1c2N0llcjJ6dTFDSUFkbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUkdMUUEwZ1daVjRQVk5BLWp5WnNHWlo4djBzSW9SWFNBN2VaSUlZWFRHRVdlS2x6LWgzb0kweFlXVWcyMjdpYS0wdmU0LTdqczdsOUhGT0owcHRzMEZ0RV8zR25zY0pnUXpZWTU1SlA2b1Rva0NHTU9QM0VSbDNqdHdhQ01nT2lQa3JVZkZzMy05RGxCckNkTE04czhOQ0xKczRGUDVybw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:24+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) plans 33,696 ADS NYSE sale after prior RSU sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQaU1USjlrNkVmSW5WVEM1RHVCZ2ZybFRVOTBSamNsV1BPZlZQUkhJbTB0UEtyckg1aUtIaHhjZjc1R2hhakQ3R1FnZFg0ZHhQTUU4dUhaSVQ0LWQ3dXpfbTJGWGZfWElDT3BtYl95YkI1b2J3Z3ZRM19GSWhNemVqYnFwMHpBbXdJZTc1T2dLWjM3bVhEck9SeWY4aXE2bFJKdU9KS01DRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:30:23+00:00", "published_display": "13 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSE", "summary": "Takeda Pharmaceutical Company Limited has filed a Form 144 notice to sell up to 7,889 American Depositary Shares (ADSs) on the NYSE through Interactive Brokers LLC, on or after July 13, 2026. The aggregate market value of these ADSs is indicated as $132,148.97. The filing also no", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-37c282f29f2d.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:11", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filing", "summary": "Takeda Pharmaceutical Company Limited filed a Form 144 SEC notice regarding the proposed sale of 190,406 American Depositary Shares (ADSs) on the NYSE. These ADSs were acquired through vested Restricted Stock Unit Awards as part of compensation on July 1, 2026. Interactive Broker", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-38c4d25bcb86.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:10", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850", "summary": "Takeda Pharmaceutical Company Limited has filed a Form 144 notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC. The aggregate market value of these shares is approximately $416,850 and the sale is expected to occur on or about ", "url": "https://www.stocktitan.net/sec-filings/TAK/144-takeda-pharmaceutical-co-ltd-sec-filing-7acd19367ec8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:10:10", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TAK) Launches Plasma Ecosystem Initiative in Indonesia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMGk2ejgzTlRSUEgyY01Iam5Fa1MteVBuRnRBZk9nbHF4Z3ZWT2JBdktXM0k4am5UYnJuaDUzVEEtWDJ6TVpKOUJhelVtM3U3cXpTNTdLbGJhU19kSWVaLVZ2V1o5c0FzUVdLTGh6QjF6TGMyR2VfWGFLRE1GYjQzejM1c2EtdG5fUmFiZFYxaS1vYm1meEZtZXFRRjA4bVlUUVVoSTRDeGJuWmNhTV9uRUZMYkRkYmFUTlVNQ3dOTUY1NWhTd3hYYUZtU0Fad25PQUEta2ZZT1dMalRwbFJseF9yU3NqN3U0Q1E?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T09:03:23+00:00", "published_display": "13 Jul 2026 09:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda and Indonesia partner on plasma-derived therapies", "summary": "Takeda is collaborating with the Indonesian Government to establish a plasma ecosystem and improve access to plasma-derived medicinal products (PDMPs) in Indonesia. The company plans to invest up to $30 million to launch a national plasma donation pilot program, with initial dona", "url": "https://www.pharmaceutical-technology.com/news/takeda-indonesia-plasma-derived-therapies/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-13T09:45:08", "published_display": "13 Jul 2026 09:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, Takeda and Capricor on the verge of notching big drug approvals", "summary": "", "url": "https://finance.yahoo.com/m/84010ace-bef0-3bf0-b760-6f87a2290af8/moderna%2C-takeda-and-capricor.html", "source_name": "Pharma Voice", "published_at": "2026-07-13T08:20:00+00:00", "published_display": "13 Jul 2026 08:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda, Indonesian Government Launch Program to Build National Plasma Ecosystem", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/takeda-indonesian-government-launch-program-074538219.html", "source_name": "MT Newswires", "published_at": "2026-07-13T07:45:38+00:00", "published_display": "13 Jul 2026 07:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/takeda-indonesian-government-announce-landmark-230000564.html", "source_name": "Business Wire", "published_at": "2026-07-12T23:00:00+00:00", "published_display": "12 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indonesia backs Takeda plan for national plasma donation network and new jobs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcHpvRG1iVnQxMlp4R3RqYnJZWlN4a3lrT2lkbmtsZTkwel9faGxOYVlpMGZkdGlaSEFnN1NVdmNmX2s4UWE1T0hxVFdpdGxPQ2ZfVlN0Umx0RTM4YkRxRXotSDhfVVlQTUJCQWU3bXU2dno2OVNEWTA0WVA0a3NLOGktY3pKYVBPZGdXRFpaa1RDRjZsNFlNM3NibzVVOGJyTFZjcFVIY3hPMVRIQWphOVJ4anB1SzNYUkRiNWpzbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-12T23:00:00+00:00", "published_display": "12 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) TD Cowen 46th Annual Health Care Conference summary", "summary": "Takeda Pharmaceutical Company presented at the TD Cowen 46th Annual Health Care Conference, highlighting a strategic overview that included successful Phase III results for three new molecular entities (rusfertide, oveporexton, and zasocitinib) in 2025 and an upcoming CEO transit", "url": "https://quartr.com/events/takeda-pharmaceutical-company-4502-td-cowen-46th-annual-health-care-conference_3sW6PWd4", "source_name": "Quartr", "published_at": "2026-07-11T23:10:10", "published_display": "11 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Study Update Summary", "summary": "Takeda Pharmaceutical Company (4502) released a study update for Oveporexton, an oral orexin receptor 2 agonist, which showed significant and clinically meaningful improvements in treating narcolepsy type 1 (NT1) across multiple endpoints. Two global Phase III trials demonstrated", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-study-update_3sW6gnqy", "source_name": "Quartr", "published_at": "2026-07-11T10:39:43", "published_display": "11 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?", "summary": "Takeda Pharmaceutical (TSE:4502) has partnered with Insilico Medicine's Pharma.AI platform for drug discovery, leading to renewed investor interest. Despite an 8.5% year-to-date share price increase and a 26.82% one-year return, a recent 90-day decline of 6.94% prompts questions ", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-pharmaceutical-tse4502-taps-pharmaai-for-drug-discove/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:40:29", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) outlines board independence, ESG and shareholder engagement", "summary": "Takeda Pharmaceutical Company Limited has filed a detailed Corporate Governance Report, highlighting its compliance with Japan\u2019s Corporate Governance Code. The report emphasizes the company's commitment to board independence with a majority of independent external directors, robu", "url": "https://www.stocktitan.net/sec-filings/TAK/6-k-takeda-pharmaceutical-co-ltd-current-report-foreign-issuer-66709a178019.html", "source_name": "Stock Titan", "published_at": "2026-07-09T09:48:28", "published_display": "09 Jul 2026 09:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Q4 2025 earnings summary", "summary": "Takeda Pharmaceutical Company announced its Q4 2025 earnings, reporting significant revenue and core operating profit growth, driven by strong performance in growth and launch products. The company also highlighted efficiency program successes, pipeline advancements, and an incre", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-q4-2025_3sW6gxaK", "source_name": "Quartr", "published_at": "2026-07-08T22:11:54", "published_display": "08 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Plan", "summary": "Takeda Pharmaceutical announced it has completed the issuance and disposal of shares as part of its incentive plan. The shares were allocated to a trust for the \"Board Benefit Trust (BBT)\" and \"Employee Stock Ownership Plan (ESOP)\" schemes. This move aims to enhance shareholder v", "url": "https://www.moomoo.com/news/post/72648686/takeda-pharmaceutical-completes-share-issuance-disposal-under-incentive-plan", "source_name": "Moomoo", "published_at": "2026-07-08T12:42:14", "published_display": "08 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical Company (4502) Q1 2026 earnings summary", "summary": "Takeda Pharmaceutical Company's Q1 FY2025 revenue declined 8.4% year-over-year to JPY 1,106.7 billion due to Vyvanse's generic erosion and FX headwinds, but net profit rose 30.4% to JPY 124.2 billion. Growth and launch products, comprising 50% of revenue, grew 5% at CER, showing ", "url": "https://quartr.com/events/takeda-pharmaceutical-company-limited-4502-q1-2026_3sW6goVg", "source_name": "Quartr", "published_at": "2026-07-08T09:42:14", "published_display": "08 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) completes long-term incentive share issuance and treasury share disposal", "summary": "Takeda Pharmaceutical Company Limited announced the completion of its long-term incentive share issuance and treasury share disposal for employees outside Japan. The company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, totaling 85,229,400,450 yen. Thi", "url": "https://www.stocktitan.net/sec-filings/TAK/6-k-takeda-pharmaceutical-co-ltd-current-report-foreign-issuer-6287e1e9db04.html", "source_name": "Stock Titan", "published_at": "2026-07-08T09:40:50", "published_display": "08 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda\u2019s orexin program: The hits, the misses and the payoff", "summary": "Takeda is nearing the market with oveporexton (TAK-861), an OX2R agonist for narcolepsy type 1, after decades of research into orexin signaling's link to the disease. The company's success is attributed to its unwavering commitment, rapid adaptations to trial designs, and strong ", "url": "https://www.biocentury.com/article/659997/takeda-s-orexin-program-the-hits-the-misses-and-the-payoff", "source_name": "BioCentury", "published_at": "2026-07-08T00:13:00", "published_display": "08 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) director Bruce Broussard receives 3,800 ADS RSUs and 1,319 tax awards", "summary": "Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard received 3,800 American Depositary Shares (ADS) as restricted stock units (RSUs) and 1,319 Tax Obligation Award units. These equity-based awards, rather than open-market purchases, vest on June 1, 2029, and increase his d", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-89f6a95cdac9.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:40:50", "published_display": "07 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 22,570 RSUs to chief HR executive", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNNk9FbDJxSUFVbl9ibmkzVDNMOXpsSEtNZmxqYlNRU0Z6aV9SeVJtZ1JzdnlRMFVBOTdmVE1CdVk5ZGI1UnVqV1NncTVLcVJKU25Fa25iY2JqWE1BU3NNbGdOaTY1UUdlSW9qZzAzcXRtOXhtMWhWN196MHcyMXg1TnNqc3dJd3RGYXlUOTZ0VXhPVGVNcDBVV3hvZzkxQXBXU21qbHFNYmdfMENXcHRXZFdDbWF6RXUzWW1sNFl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:06:58+00:00", "published_display": "06 Jul 2026 22:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 27,586 RSUs to strategy head Marcello Pignagnoli", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaVlEX19vX1lmWWxwNHEtdFpSU3pibkNxUDhMak1RcERpLUlBQTh1RzF4RWt1V0Yzam42SlVleGlvT2h2QWJqbWtKNV9TcG51UTNiV1N6SXdWaXRCRnlGaG1sN180WXp6NU0wX25ZUE5ibHdMOTBNcG9CTkJSNHZiS2dMTXRNTU1lWjAzcTRyRW8xRW5IbV9iTk15VkJUZTRGXzE2c0E3aXNyWFVLc09DMldzVUEwSVhVZ0RwWjhR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:05:10+00:00", "published_display": "06 Jul 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) R&D head receives 125,390 RSUs, updates holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOLVBGOUhkelgxQjlOS0pIS2pJbHNMRWZkdi1KYkZRUWFiRGppdWVQWGhxeGJPdGFrYUxIb1g4ZkUyRDFPTTZmSlhsMXdrODRsYkpnT1dERHhLOFNtM29HenBqRDNOVk56UDBaaXZaeTl1c25fbFdNZVNLZ1BjYVpndTdUaXpoNlYxazFvYkdGMGtQR3hVVFUzT2lPYjYwclhUdDNtZ3ozc3hUbWRneUQ1MHp1X1k2dWphLXhRWjZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T22:01:36+00:00", "published_display": "06 Jul 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 49,558 ADS RSUs to IBU president Platford", "summary": "Takeda Pharmaceutical (NYSE: TAK) granted 49,558 American Depositary Shares (ADS) as Restricted Stock Units (RSUs) to Giles Richard Platford, President, IBU, as part of his compensation. These RSUs were awarded at no cash cost and will vest in three equal annual installments star", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-788156463a7c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director gets RSU grant and manages tax-related share disposition", "summary": "Takeda Pharmaceutical director Kimberly A. Reed reported new equity awards and tax-related share transactions. She received a grant of 3,800 Ordinary Shares as restricted stock units vesting on June 1, 2029, and 1,319 Tax Obligation Awards. Additionally, 1,152 Tax Obligation Awar", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b57beba8c391.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) executive granted 30,094 RSUs, lifting holdings to 87,674 ADS", "summary": "Takeda Pharmaceutical executive Shannon Elaine Mary received a grant of 30,094 Restricted Stock Units (RSUs), increasing her total holdings to 87,674 American Depositary Shares (ADS). These RSUs, which were awarded as part of compensation at a $0.00 stated price, will vest in thr", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-39c2d023174c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) chief communications officer receives 18,808 RSU share award", "summary": "Takeda Pharmaceutical's Chief Communications & Government Officer, Jennifer Marie Smoter, was granted an equity award of 18,808 American Depositary Shares in the form of restricted stock units (RSUs). These RSUs will vest in three equal annual installments starting on July 1, 202", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-bf62fcd1cda7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) grants 37,616 ADS RSUs to tech chief Ricci", "summary": "Takeda Pharmaceutical (NYSE: TAK) has granted its Chief Data & Technology Officer, Gabriele Ricci, 37,616 American Depositary Shares (ADS) in the form of restricted stock units (RSUs). These RSUs were awarded at no cost and will vest in three equal annual installments beginning J", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b78bf3c22de2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) unit president gets RSU grant and tax awards", "summary": "Asuka Miyabashira, President of Takeda Pharmaceutical's Japan Pharma Business Unit, received a grant of 1,500 Ordinary Shares and several Tax Obligation Awards. This transaction increased her direct ownership to 4,500 shares. Additionally, 1,022 vested Tax Obligation Awards were ", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-413d92923acf.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:11:56", "published_display": "06 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director Paulus Stoffels receives share and tax-linked awards", "summary": "Takeda director Paulus Stoffels reported receiving equity compensation, including 3,800 Ordinary Shares and 1,307 Tax Obligation Awards. These awards are part of his director compensation, with the shares going into his direct holdings and the tax awards vesting as cash on June 1", "url": "https://www.stocktitan.net/sec-filings/TAK/form-4-takeda-pharmaceutical-co-ltd-insider-trading-activity-b610520200b2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:11:56", "published_display": "06 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Paulus Stoffels files initial Form 3 for Takeda (NYSE: TAK)", "summary": "Takeda director Paulus Stoffels has filed an initial Form 3 with the SEC, indicating his insider status as a director of the company. This filing is a baseline disclosure and reports no transactions or derivative positions in Takeda's securities. It serves to establish his benefi", "url": "https://www.stocktitan.net/sec-filings/TAK/form-3-takeda-pharmaceutical-co-ltd-initial-statement-of-beneficial-o-e98ee9e0a095.html", "source_name": "Stock Titan", "published_at": "2026-07-06T15:42:33", "published_display": "06 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 43,886 RSU-linked ADSs to oncology unit chief", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOFRKNlB2aGNkZk1HaktnU0t2cDA4RGNxTGVRUVppLTBsMkktaHd6U1lZelhkdWFTbF9KSzVMT0NUQ0FTOVFFNTUyaGNSaXZkaXVvVUJzSU9vejhQZFNXUEs5SlhVN0NrWFlscGZDZFZhVjA0eUxwTHlkS0phLXY5c3AzYmdINEJXdndwR1ZwMkpnMk5ZZmVfYXhyTkVEMlZsWDVkc29Dc25aMEdvZUI5WTl3WEZaQTNqVnJFSjRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TAK) U.S. Business president awarded 50,156 RSUs in ADS grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQVzg3UVZUTEd5cDJPVHdManZiSUZCQzdjSFlpNldudnIzMG1PX0tLMTA1ek1nUkJCa0tiZWlxRGE4U1NPMXFaQ1BvaEdrMTNqRHNTbUVNd2NNdUtHVng4UmhpdVZMRDVEUktYSzRubWZYbUltYUN2dHlIS056cktNUFE5QVY3Z0VXeVlpMlMzeDZfVi02V3ZicnBpbGd1UE5FcjloYUNtanpBZkd0VWlIVS0xTGNZeVh0X2FfajJR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director awarded RSUs and settles tax obligation awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQejFvMUxrYXJTS285T2Z2ZVJSanVkT0dEX3BiV0c5dExLSk91aUlTSkt3MkJMbUhPUVQ0dDZOZUd3Nm5RZ3ZfU01CU0c5eEozS3NWWkVESS1JR2tXMjBXZzVNM05lb2xxQWctVWFKQ1hqOWpSQTJkdjYtT3EydGpPMlVaX1B6TXBVXzRzangyUEZoU0Vra29kZGhpenREUU8yOUNaaHZyVmhoY2x1TGdZeU9xd3cwUGw3a2ZEbmln?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) awards 45,140 RSUs to Chief Transformation Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbk9jdTlYTWJLSmRBRkhUWFlOOWNtd2ljMXpyTlB3RnlhdDNWaGlXLTRxUWlwSGlTSVM1ckRMc09UTnZ2c0F6VHVqSEI3S0J4YkFHOTJZR0JFbmVmd1p4b2ppQ1BNWTFEYnZhYXRBLUI4YWV6WS00azF0UXZQWmZnT0hlemhpellTVm9Sai1FSWlSYUJwMV82QkhxOXdfTTFic3l5emI1TU41d0VmeG0xZUdsMkNQblFOX1BzQlh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (NYSE: TAK) director logs RSU awards and tax-related share disposition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNZDFmb3BzTDc3UHVzWnkybVFuWml2RlptLU4wUGNJRWx0RDMxNk1PV21fbXdMbEN3WjlhYjdJSGxKdDBBUmNrUVhZaDZNZUx6cm9jWnJJRFItOHVmcEo3Wnp1SEJXVU9MLUJwQ2dDbF9ZdS1MeWROYmdIR0RUaXgtdXRVR3c3Zmc0b1pnNWlDeG5nQTZoYUc5RzZGdURxNHRKN3FKSUwxenI5WWZ3dF8ySkZ4b09ybS1WeW96R1dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?", "summary": "Takeda Pharmaceutical's stock rose 5.3% following its collaboration with Insilico Medicine to use its Pharma.AI platform for drug discovery, a deal potentially worth up to US$600 million plus royalties. This partnership, alongside the new CEO Julie Kim, could significantly influe", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-pharmaceutical-tse4502-is-up-53-after-new-insilico-ai/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T03:40:22", "published_display": "06 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks", "summary": "This article lists various ETFs that include Takeda Pharmaceutical Co. Ltd. Sponsored ADR stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of Takeda stock, issuer, management style, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/LSE-0A87/etfs/", "source_name": "TradingView", "published_at": "2026-07-06T03:40:22", "published_display": "06 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine", "summary": "", "url": "https://finance.yahoo.com/technology/ai/articles/takeda-makes-fresh-ai-drug-173105795.html", "source_name": "Benzinga", "published_at": "2026-07-05T17:31:05+00:00", "published_display": "05 Jul 2026 17:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda (TSE:4502) Stock Still Looks Slightly Undervalued Overall", "summary": "Takeda Pharmaceutical (TSE:4502) stock has shown strong returns over the past five years but presents a nuanced valuation picture, screening as undervalued in 4 of 6 checks according to Simply Wall St's framework. The company's P/S ratio of 1.9x is slightly above the industry ave", "url": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4502/takeda-pharmaceutical-shares/news/takeda-tse4502-stock-still-looks-slightly-undervalued-overal/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-04T08:10:03", "published_display": "04 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOMnlTVE96dXFleVkwdWRIQlhkc1VHWWhjSG1qbmVhVVRjYm83NzBOaWczNHZJMm5fQjRoY21SRXc5V1BKalk1RHhocXZJU1BhdmhwVUUtVTUybDNUUFd5MzdjSjZIVVNwQ3hwQ3p5WGgyeGtBZ2Nad2laTXpVM3YxQ0s5bjhhemJlVUZwMFdZS25Sak52cTAzd0d2S1YwWjZBVVFHRw?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda appoints Julie Kim CEO as 18-month transition ends", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTDFIVEpPX3pkdmUtZ2VidzZ6aFhQeVpEQlBQSHBDT1o0OGs2N0tEcU5tVkttT3NibU1qeXl4OXhoOW1US00zSHJhSGFsZVNKczd4R24yLUxlOGNkb2Z4YnFEVU9aTGUweGRpallGWGs2V1htOThUdHM5eWxjRk1wOExUbWZTSk5wdzlsMzZNdXo3bUYwaGJ4QVRRWmkwX1RzU1FlMVBmYXhPZ2J3anFtdGtCRGFjUWliVlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda Pharmaceutical: The Downside Was Forecastable (NYSE:TAK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOY3BEQzFhQ0I0dTNQTEFZVnRFXzdadzRDNlhRZ2h5cXNCNFVIbnRtVi1Ydnd4TmJHdHBOYmVTWjgwbkQtekZRRTRsRDFTVGJGR2tWbnhpdXRfanZQS0xhZGo4WmRja3l6cG0wN1B5Z3F5ZUR4YzJNYllONmE4bXBsV3hiUjJsRVpJaHc3OEU3cTFQVDlkWTJn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQRkFWZ3o4c21ET2tVMzVGNDFhVS1OZnhIZU5uOEh5akxTT2JuV0ZvaEtLRl9DNHZBS1VwOVZWNlBnZEdYOVYta0ZnbmNmaUhoVDFURjJqT1QyZnBPWjJzenlmUnc5dGhyeW5NUWN0V1JyTE12WEtaVEluUm8wQ1FwLUdXZVFfU1JFTEhha0lmcXcxaF9hd19jcTZmSzY3N1F5cWlPal9jbGNIajNhbFQ4?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNckpfeDdTSDBxVTFueWdHZHRya2tPcDVKdWxJR005c0Q1MjdNRXE0cG1OalM2LW1yMUxuekZXOHhlRFcydVlibUgwVnNSRkdQd2lRTUhhR0ItVk5ub2loSGFzanNwX1BLLXlpZklYc3RXTWJodDdWNU0wLTd3dXBPOXBCV3VhdGZSb2FzTzk2SmNLTkRfcFJOV3E2YnJwOEFzdjRMQkNROHlxOGwxRVRR?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPV2EwUkxKSVZNaEJLQ0o0NHFHdFZmQ29LTmt1NklBdnVFTHVueHZRTWRTSktZSk1BM1l6LS1sa1RTTXNnOEYtSUcyZ2JBU1V5a0pjRkRiOF9iN1hWNjRqOFpPalRTN0cydVNfbVM1NnB3MERnYmJWOFFKcmM4eE9aMzBabV9mTGgtUUN0dHpTWXM?oc=5", "source_name": "Market source", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 88, "total_relevant": 59, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 40, "score": 53, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 90, "events": [{"event": "general", "label": "Market update", "weight": 28.4, "count": 51}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 16.56, "latest_week": "2026-07-10", "one_week_move": -1.3, "four_week_move": 4.1, "twelve_week_move": -7.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.892413, "market_dynamics_buy_signal": false, "relative_strength": -5.656294, "fair_value_gap": 16.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.7328, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.3% over one week, +4.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 34}, {"label": "Quartr", "count": 5}, {"label": "Market source", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "www.marketscreener.com", "count": 1}, {"label": "Jakarta Globe", "count": 1}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "GuruFocus", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 51}, {"label": "Earnings", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "90/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.3% over one week, +4.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30"}], "updated_at": "2026-07-16T11:50:59.119055+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}